Drug Profile
Prasinezumab - Prothena Corporation/Roche
Alternative Names: NEOD-002; PRX-002; RG 7935; RO 7046015Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Neotope Biosciences
- Developer Chugai Pharmaceutical; Prothena; Roche
- Class Antiparkinsonians; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Alpha-synuclein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Parkinson's disease
Most Recent Events
- 03 Aug 2023 Roche completes enrolment in the phase IIb PADOVA trial in Parkinson's disease (Early-stage disease) in USA, Austria, Canada, France, Italy, Luxembourg, Poland, Spain and United Kingdom (IV) (NCT04777331)
- 21 Jun 2023 Roche plans regulatory filing for Parkinson's disease, in 2026 or beyond (Roche pipeline, June 2023)
- 28 Apr 2023 Updated efficacy data from the phase II trial PASADENA in Parkinson's disease presented at the 75th Annual Meeting of the American Academy of Neurology (AAN-2023)